Istanbul Medipol University Faculty of Medicine, Department of Physical Medicine and Rehabilitation, Istanbul, Turkey.
Karaman Medical Center, Department of Physical Medicine and Rehabilitation, Karaman, Turkey.
Acta Chir Orthop Traumatol Cech. 2021;88(2):117-123.
PURPOSE OF THE STUDY The objective of the present study is to compare the efficacy of two different concentrations of diclofenac sodium phonophoresis (DSPH) (1.16% vs 2.32%) in patients with knee osteoarthritis (OA). MATERIAL AND METHODS A randomized, double-blind, controlled design was applied. Ninety patients (mean age± SD, 59.98 ± 8.89 years) who had Kellgren-Lawrence (K-L) grades II to III knee OA were randomly allocated into three groups; 1.16% DSPH, 2.32% DSPH, TUS (30 in each group). Each patient was treated five sessions per week for two weeks. A 100-mm visual analogue scale (VAS) for usual pain and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) were evaluated before and after treatment in all groups. RESULTS The VAS pain and WOMAC scores were significantly improved after treatment in all groups (p < 0.05). The 2.32% DSPH showed more significant effects than the 1.16% DSPH, both in improving WOMAC- pain and physical function scores (p = 0.020, p = 0.008) and reducing the VAS pain measure, although it did not reach the level of significance (p = 0.077). The 2.32% DSPH was superior to the TUS, both in reducing the VAS pain measure (p < 0.001) and in improving WOMAC-pain, stiffness, physical function and total scores (p = 0.022, p = 0.016, p < 0.001, p < 0.001 respectively). 1.16% DSPH significantly reduced stiffness and physical function scores compared with TUS (p = 0.042, p = 0.047). CONCLUSIONS DSPH and TUS are effective treatments for knee OA. Our results indicated that 2.32% DSPH produces additional benefits to functional improvement and pain reduction compared with 1.16% DSPH in K-L grades II to III knee OA. Key words: diclofenac sodium, knee osteoarthritis, phonophoresis, therapeutic ultrasound, topical formulation.
本研究旨在比较两种不同浓度的双氯芬酸钠声透入疗法(DSPH)(1.16%对 2.32%)在膝骨关节炎(OA)患者中的疗效。
采用随机、双盲、对照设计。90 例(平均年龄±标准差,59.98±8.89 岁)Kellgren-Lawrence(K-L)分级 II 至 III 级膝 OA 患者随机分为三组;1.16%DSPH、2.32%DSPH、TUS(每组 30 例)。每组患者每周治疗 5 次,共治疗 2 周。所有患者在治疗前后均采用 100mm 视觉模拟评分(VAS)评估常规疼痛和西部安大略省和麦克马斯特大学骨关节炎指数(WOMAC)。
所有患者治疗后 VAS 疼痛和 WOMAC 评分均显著改善(p<0.05)。2.32%DSPH 在改善 WOMAC-疼痛和躯体功能评分方面优于 1.16%DSPH(p=0.020,p=0.008),降低 VAS 疼痛评分虽未达到统计学意义(p=0.077)。2.32%DSPH 在降低 VAS 疼痛评分(p<0.001)和改善 WOMAC-疼痛、僵硬、躯体功能和总分方面均优于 TUS(p=0.022,p=0.016,p<0.001,p<0.001)。1.16%DSPH 与 TUS 相比,僵硬和躯体功能评分显著降低(p=0.042,p=0.047)。
DSPH 和 TUS 是治疗膝 OA 的有效方法。我们的结果表明,2.32%DSPH 在 K-L 分级 II 至 III 级膝 OA 患者中比 1.16%DSPH 更能改善功能和减轻疼痛。
双氯芬酸钠、膝骨关节炎、声透入、治疗性超声、局部制剂。